News
-
Armata Pharmaceuticals announced that the Cystic Fibrosis Foundation has purchased $3 million worth of the company’s common stock and that Innoviva subsidiary Innoviva Strategic Opportunities, which already held a significant number of shares in Armata,… Read more . . .
-
According to TFF Pharmaceuticals, Health Canada has issued a no objection letter regarding a Phase 1 clinical trial of TFF’s dry powder inhaled niclosamide that will evaluate 0.5, 2, and 6 mg doses in healthy volunteers… Read more . . .
-
Inhaler testing equipment company Copley Scientific is introducing a new nasal dose uniformity sampling apparatus (DUSA) interface plate designed to work with the company’s Vertus II/Plus shake and fire system for delivered dose uniformity testing… Read more . . .
-
Meissa Vaccines has announced that interim data from a Phase 1 study of its MV-014-212 intranasal recombinant live attenuated COVID-19 vaccine demonstrate that a single dose produced a good nasal IgA response with no reported… Read more . . .
-
Device company Nemera has announced the launch of a new single metered dose nasal pump called UniSpray, which is designed for delivery of systemic drugs. According to the company, UniSpray requires no priming, is compatible… Read more . . .
-
Why should inhaled drug developers consider formulating or reformulating with HFA 152a? It became very clear to us about 6 or 7 years ago that regulatory efforts to reduce global warming potential emissions in industrial… Read more . . .
-
Device developer Cambridge Healthcare Innovations (CHI) has announced the appointment of former AuroScience Head of Device Development Philip Canner as CEO. In addition to AuroScience, an Aurobindo subsidiary that develops generic inhaled drugs, Canner’s OINDP… Read more . . .
-
According to Inhalation Sciences (ISAB), a US patent covering the XposeALI in vitro cell culturing module has been extended until 2034. US Patent No. 11054414 (“Exposure system”) was originally filed in 2013, the company said. The… Read more . . .
-
Beckley Psytech said that it has initiated dosing in a Phase 1 trial of its intranasal 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), a psychedelic compound found in the secretions of certain toads. The company is developing the intranasal formulation… Read more . . .
-
ReCode Therapeutics has raised $80 million in Series B financing that it will use in large part to fund clinical development of inhaled therapies for cystic fibrosis and primary ciliary dyskinesia (PCD), the company said.… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK


